<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04102605</url>
  </required_header>
  <id_info>
    <org_study_id>DB_NV_P01</org_study_id>
    <nct_id>NCT04102605</nct_id>
  </id_info>
  <brief_title>Visual Perceptual Learning for the Treatment of Visual Field Defect</brief_title>
  <acronym>VIVID2</acronym>
  <official_title>Efficacy and Safety of Visual Perceptual Learning Using the Nunap Vision for Improvement of Visual Field Defect Caused by Brain Damage: Multi Center, Superiority Prove, Double-blind, Randomized, Confirmatory Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nunaps Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nunaps Inc</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the efficacy of visual perceptual learning for the treatment of visual
      field defect caused by brain damage. Half of participants will receive visual perceptual
      training using the Nunap Vision, while the other half will receive sham training using the
      Nunap Vision-C.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 17, 2019</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area of Humphrey visual field where sensitivity increased by equal or more than 6 dB relative to baseline</measure>
    <time_frame>12 weeks</time_frame>
    <description>Improved regions have luminance sensitivity that increased by equal or more than 6 dB relative to baseline. The improved area ranges between 0 and 972 degree^2, of which larger area indicates better outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Humphrey visual field mean deviation relative to baseline</measure>
    <time_frame>12 weeks</time_frame>
    <description>Changes in mean deviation value of whole field or defect field compared with the baseline value. The change of mean deviation ranges between -35 to +35 dB, of which higher value indicates better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in scores of NEI-VFQ-25(the National Eye Institute Visual Function Questionnaire 25) relative to baseline</measure>
    <time_frame>12 weeks</time_frame>
    <description>Changes in each components of NEI-VFQ-25 scores relative to baseline. The change of scores ranges between -100 to 100, of which higher value indicates better outcome.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Visual Fields Hemianopsia</condition>
  <condition>Hemianopsia, Homonymous</condition>
  <arm_group>
    <arm_group_label>Nunap Vision</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nunap Vision , 5 days a week for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nunap Vision-C</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Nunap Vision-C, 5 days a week for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Nunap Vision</intervention_name>
    <description>Participants receive visual perceptual training using the Nunap Vision software</description>
    <arm_group_label>Nunap Vision</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Nunap Vision-C</intervention_name>
    <description>Participants receive sham training using the Nunap Vision-C software</description>
    <arm_group_label>Nunap Vision-C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 19-80 years

          -  Stroke-induced visual field defect

          -  At least 6 months after stroke

          -  Verified visual pathway damage using CT or MRI

          -  K-MMSE(Korean Mini Mental Status Examination) score ≥ 24

          -  Visual acuity equal or better than 20/40

          -  Able to use the investigational device

          -  Patient/legally authorized representative has signed the informed consent form

        Exclusion Criteria:

          -  Unreliable Humphrey visual field test (any of fixation loss, false positive, false
             negative ≥ 20%)

          -  Complete hemianopsia with sensitivity of the whole hemifield ≤ 3 dB

          -  Damage to the pulvinar or lateral geniculate body on brain imaging

          -  Comorbid neurological disorders other than stroke

          -  Bilateral visual field defect

          -  Hemispatial neglect

          -  Ophthalmologic disorder that may interfere the trial

          -  Inability to discontinue psychostimulants such as methylphenidate, modafinil, and
             amphetamine.

          -  Candidate for carotid endarterectomy or stenting

          -  Received ophthalmologic surgery within 3 months, except for the cataract surgery

          -  Pregnant or breast feeding

          -  Participating in other clinical trial

          -  Any other condition that, in the opinion of the investigator, precludes participation
             in the trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dong-Wha Kang, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Nunaps Inc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hyun-Wook Nah, MD, PhD</last_name>
    <phone>+82-2-488-6533</phone>
    <email>hyunwook.nah@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <state>Kyunggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Moon-Ku Han, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sun U. Kwon, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chung-Ang University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kwang-Yeol Park, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Konkuk University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hahn Young Kim, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gyeong-Moon Kim, MD, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>September 23, 2019</study_first_submitted>
  <study_first_submitted_qc>September 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 25, 2019</study_first_posted>
  <last_update_submitted>April 27, 2020</last_update_submitted>
  <last_update_submitted_qc>April 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Visual field defect</keyword>
  <keyword>visual perceptual learning</keyword>
  <keyword>Humphrey visual field</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemianopsia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

